⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14230588 | 0.75 | — | — | |
| SCHEMBL13152125 | 0.75 | — | — | |
| SCHEMBL572548 | 0.75 | — | — | |
| SCHEMBL10095234 | 0.75 | — | — | |
| SCHEMBL17931743 | 0.69 | — | — | |
| SCHEMBL9369304 | 0.65 | — | — | |
| SCHEMBL29306952 | 0.65 | — | — | |
| SCHEMBL4402595 | 0.63 | — | — | |
| SCHEMBL287099 | 0.63 | — | — | |
| SCHEMBL11773919 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5461044-A | High concentration in blood; orally or injectable administrable | MEIJI SEIKA KAISHA, LTD. (JP) | 1995-10-24 | — | — | US | claimed |
| US-20230272077-A1 | PD-1 SIGNAL INHIBITOR COMBINATION THERAPY | KYOTO UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230265193-A1 | PD-1 SIGNAL INHIBITOR COMBINATION THERAPY | KYOTO UNIVERSITY (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-4218819-A2 | COMBINATION THERAPY BASED ON PD-1 SIGNAL INHIBITORS | Kyoto University (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-20200129582-A1 | NOVEL PEPTIDES AND PEPTIDOMIMETICS | INFLAMMX THERAPEUTICS, INC. | 2020-04-30 | — | — | US | disclosed |
| EP-2744506-B1 | CARDIOVASCULAR THERAPEUTICS | UPSTREAM MEDICAL TECH LIMITED (NZ) | 2019-10-09 | — | — | EP | disclosed |
| EP-3452072-A2 | NOVEL PEPTIDES AND PEPTIDOMIMETICS | University of Auckland (NZ) | 2019-03-13 | — | — | EP | disclosed |
| US-20180362650-A1 | PD-1 SIGNAL INHIBITOR COMBINATION THERAPY | KYOTO UNIVERSITY (JP) | 2018-12-20 | — | — | US | disclosed |
| EP-3388084-A1 | PD-1 SIGNAL INHIBITOR COMBINATION THERAPY | Kyoto University (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20180148475-A1 | Cardiovascular Therapeutics | UNIVERSITY OF OTAGO (NZ) | 2018-05-31 | — | — | US | disclosed |
| US-20180008664-A1 | NOVEL PEPTIDES AND PEPTIDOMIMETICS | INFLAMMX THERAPEUTICS, INC. | 2018-01-11 | — | — | US | disclosed |
| WO-2017192620-A2 | NOVEL PEPTIDES AND PEPTIDOMIMETICS | UNIVERSITY OF AUCKLAND (NZ) | 2017-11-09 | — | — | WO | disclosed |
| US-9783574-B2 | Cardiovascular therapeutics | OTAGO INNOVATION LIMITED (NZ) | 2017-10-10 | — | — | US | disclosed |
| US-9260500-B2 | Peptide and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-2744506-A2 | CARDIOVASCULAR THERAPEUTICS | Otago Innovation Limited (NZ) | 2014-06-25 | — | — | EP | disclosed |
| US-20130072431-A1 | CARDIOVASCULAR THERAPEUTICS | OTAGO INNOVATION LIMITED (NZ) | 2013-03-21 | — | — | US | disclosed |
| WO-2013024362-A2 | CARDIOVASCULAR THERAPEUTICS | OTAGO INNOVATION LIMITED (NZ) | 2013-02-21 | — | — | WO | disclosed |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | disclosed |